Zacks Small Cap Comments on Cadrenal Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:CVKD)

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities researchers at Zacks Small Cap issued their Q3 2024 EPS estimates for Cadrenal Therapeutics in a note issued to investors on Monday, September 16th. Zacks Small Cap analyst D. Bautz expects that the company will post earnings of ($2.18) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($6.00) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q4 2024 earnings at ($2.18) EPS, FY2024 earnings at ($8.17) EPS, FY2025 earnings at ($2.90) EPS and FY2026 earnings at ($2.20) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $0.20 target price on shares of Cadrenal Therapeutics in a research note on Thursday, June 6th.

Cadrenal Therapeutics Price Performance

Shares of NASDAQ CVKD opened at $12.00 on Wednesday. The firm has a market capitalization of $192.10 million, a P/E ratio of -38.71 and a beta of 1.74. Cadrenal Therapeutics has a 12-month low of $5.40 and a 12-month high of $32.55.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its earnings results on Wednesday, August 7th. The company reported ($2.25) EPS for the quarter, beating analysts’ consensus estimates of ($19.04) by $16.79.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.